Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children

Pediatrics

Volumn 128, Issue 6, 2011, Pages

  Leonardi, Michael ^a   Bromberg, Kenneth ^b   Baxter, Roger ^c   Gardner, Julie L ^d   Klopfer, Stephanie ^a   Nicholson, Ouzama ^d   Brockley, Michael ^e   Trammel, James ^e   Leamy, Vicky ^f   Williams, Wendy ^d   Kuter, Barbara ^d   Schödel, Florian ^d  

^a Palmetto Pediatrics   (United States)

^b BROOKLYN HOSPITAL CENTER   (United States)

^c KAISER PERMANENTE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e i3 Statprobe   (United States)

^f i3 Research   (United States)

Author keywords

Concomitant administration; Immunization; Measles; MMRV; Mumps; PCV 7; Pneumococcal 7 valent conjugate vaccine; Rubella; Vaccine; Varicella

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CHILD; CONTROLLED STUDY; COUGHING; DIAPER DERMATITIS; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; IRRITABILITY; MALE; NORMAL HUMAN; OTITIS MEDIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

FEMALE; HUMANS; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; PNEUMOCOCCAL VACCINES;

EID: 83155176257     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-2132     Document Type: Article

References (17)

1. Centers for Disease Control and Prevention. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. 2008;57(10):258-260
2. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella: vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1998;47(1):1-57
3. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007;56(1):1- 40, CE-1-CE-4
4. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19 -35 months: United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(33):921-926
5. National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ. 2011;60(2):3-61
6. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2000;49(RR-9):1-35, CE-1-CE-6
7. Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV-7) in children aged 24 -59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep. 2008;57(13):343-344
8. Wasmuth EH, Miller WJ. Sensitive enzymelinked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol. 1990; 32(3):189-193
9. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine. 1991;9(2):111-116
10. Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW. Purification of individual varicellazoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods. 1986;14(2):177-188 (Pubitemid 17175901)
11. Li S, Chan ISF, Matthews H, et al. Inverse relationship between six week post-vaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J. 2002;21(4): 337-342 (Pubitemid 34326873)
12. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J. 1992;11(1):19-23
13. Marchese RD, Jain NT, Antonello J, et al. Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 Vaccine: assay operating characteristics and correlation to the WHO international assay [published correction appears in Clin Vaccine Immunol. 2008;15(6):1034]. Clin Vaccine Immunol. 2006;13(8):905-912
14. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2): 213-226 (Pubitemid 15055349)
15. Kuter BJ, Brown ML, Hartzel J, et al.; Study Group for ProQuad. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin. 2006;2(5):205-214
16. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009; 27(34):4656-4661
17. Shinefield H, Black S, Thear M, et al. Safety and immunogenicity of a measles, mumps, rubella, and varicella vaccine given with combined Haemophilus influenzae type B conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J. 2006;25(4):287-292